Newron Pharmaceuticals (OTCMKTS:NWPHF) vs. AEON Biopharma (NASDAQ:AEON) Head-To-Head Comparison

Newron Pharmaceuticals (OTCMKTS:NWPHF) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Profitability

This table compares Newron Pharmaceuticals and AEON Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Newron Pharmaceuticals	N/A	N/A	N/A
AEON Biopharma	N/A	N/A	-994.63%

Analyst Ratings

This is a breakdown of current ratings and price targets for Newron Pharmaceuticals and AEON Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Newron Pharmaceuticals	0	0	0	0	0.00
AEON Biopharma	0	0	1	0	3.00

AEON Biopharma has a consensus target price of $5.00, indicating a potential upside of 747.46%. Given AEON Biopharma’s stronger consensus rating and higher possible upside, analysts plainly believe AEON Biopharma is more favorable than Newron Pharmaceuticals.

Valuation & Earnings

This table compares Newron Pharmaceuticals and AEON Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Newron Pharmaceuticals	$6.82 million	24.50	-$17.63 million	N/A	N/A
AEON Biopharma	N/A	N/A	-$36.63 million	$0.18	3.28

Newron Pharmaceuticals has higher revenue and earnings than AEON Biopharma.

Risk and Volatility

Newron Pharmaceuticals has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.

Institutional & Insider Ownership

22.8% of AEON Biopharma shares are held by institutional investors. 23.5% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

AEON Biopharma beats Newron Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.